Clinical Trial Update: Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

This entry notes that the Phase 1/Phase 2 trial of copanlisib plus avelumab as maintenance therapy for advanced urothelial carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Aliqopa (copanlisib)
• BAVENCIO (AVELUMAB)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Advanced Urothelial Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN